Aktienanalyse zu Bullfrog AI Holdings Inc (BFRG)BFRGBullfrog AI Holdings Inc

Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Bullfrog AI Holdings, Inc. (BFRG) appears to be a good buy right now due to its recent positive momentum and strategic partnerships. The stock has shown a 5-day change of +4.76%, indicating a rebound, and it recently regained compliance with Nasdaq requirements, which enhances investor confidence. The current price is $0.51, significantly below its 52-week high of $1.96, suggesting potential upside. However, the company is still facing challenges with a forward P/E of 0 and a gross margin of 49.63% in the latest quarter, which indicates improving profitability but also highlights ongoing operational risks. The main risk is the high net income loss of -$1,371,530 in Q2 2026, which could impact future performance if not addressed.